Brief: XBiotech Announces First Patient Enrolled In Randomized Multi-Center Clinical Study Evaluating Bermekimab Therapy In Patients With Hidradenitis Suppurativa
23/10/2019 13:25
Oct 23 (Reuters) - XBiotech Inc XBIT.O :
* XBIOTECH ANNOUNCES FIRST PATIENT ENROLLED IN RANDOMIZED
MULTI-CENTER CLINICAL STUDY EVALUATING BERMEKIMAB THERAPY IN
PATIENTS WITH HIDRADENITIS SUPPURATIVA
Source text for Eikon: ID:nGNE96yVpC
Further company coverage: XBIT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on XBiotech
See all newsBrief: XBiotech Announces Positive Final Efficacy Results From Phase II Taskin Trial
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: XBiotech Inc - John Simard To Retire As CEO Of XBiotech - SEC Filing
Brief: Xbiotech Announces Enrollment Completion Of Phase I Clinical Trial For Hutrukin, A Novel Candidate Therapy For Stroke